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Abstract
Rationale Prenatal exposure to infection is a notable environ-
mental risk factor in the development of schizophrenia. One
prevalent hypothesis suggests that infection-induced disruption
of early prenatal brain development predisposes the organism
to long-lasting structural and functional brain abnormalities.
Many of the prenatal infection-induced functional brain
abnormalities appear to be closely associated with imbalances
in the mesocorticolimbic dopamine system in adult life,
suggesting that disruption of functional and structural dopa-
minergic development may be at the core of the developmental
neuropathology associated with psychosis-related abnormali-
ties induced by prenatal exposure to infection.
Objectives In this review, we integrate recent findings
derived from experimental models in animals with parallel
research in humans which supports this hypothesis. We
thereby highlight the developmental perspective of abnormal
DA functions following in-utero exposure to infection in
relation to the developmental and maturational mechanisms
potentially involved in schizophrenia.
Results Experimental investigations show that early prenatal
immune challenge can lead to the emergence of early
structural and functional alterations in the mesocorticolimbic
DA system, long before the onset of the full spectrum of
psychosis-associated behavioral and cognitive abnormalities
in adulthood.
Conclusions Dopaminergic mal-development in general,
and following prenatal immune activation in particular,
may represent a primary etiopathological mechanism in the
development of schizophrenia and related disorders. This
hypothesis differs from the view that dopaminergic abnor-
malities in schizophrenia may be secondary to abnormalities
in other brain structures and/or neurotransmitter systems.
The existence of primary dopaminergic mechanisms may
have important implications for the identification and early
treatment of individuals prodromally symptomatic for
schizophrenia.
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Introduction
Schizophrenia is a major form of psychotic disorder that
affects approximately 1% of the population worldwide
(Tamminga and Holcomb 2005; Ross et al. 2006). It is
characterized by profound disturbances in mental functions,
emotions, and behavior. Multiple lines of evidence suggest
that this disabling brain disorder is of neurodevelopmental
origin, in which the primary cerebral insult or pathological
process occurs during early brain development, long before
the illness is clinically manifest (Weinberger 1987; Murray
et al. 1992; Rapoport et al. 2005). According to this
hypothesis, an interaction between early neurodevelopmen-
tal disturbances and peri-adolescent brain maturation seems
to be necessary in order to trigger the onset of full-blown
psychotic behavior, which typically emerges during ado-
lescence or early adulthood. A recent refinement of this
hypothesis emphasizes the progressive nature of the
changes which occur during and subsequent to the onset
of full-blown psychosis (Pantelis et al. 2005a, b; Wood
et al. 2008).
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It has long been recognized that schizophrenia is a
heritable disorder that probably involves multiple genes
with relatively modest effects across large populations
(Harrison and Weinberger 2005; Ross et al. 2005). At least
some of the early neurodevelopmental disturbances may be
accounted for by abnormal expression of genes that are
essential for early neurodevelopmental processes. Indeed,
many of the recently identified susceptibility genes are
known to have essential functions in early neurodevelopment,
including neuronal differentiation, survival, synaptogenesis,
and apoptosis (Harrison and Weinberger 2005; Ross et al.
2005). Besides genetic etiopathological contributions, various
environmental factors can increase the risk of schizophrenia
and other psychosis-related disorders (McDonald and Murray
2000; Dean and Murray 2005; Opler and Susser 2005). Many
of these factors operate at prenatal or early postnatal stages of
life, that is, during the critical periods of early central nervous
system (CNS) development. Environmental insults targeting
early brain development may thus bring additional risk
towards altering neurodevelopmental trajectories and long-
term brain functions relevant to schizophrenia.
Maternal infection during pregnancy is one of the known
environmental factors that can significantly increase the risk
of schizophrenia and related disorders in the offspring (for
recent reviews, see Brown and Susser 2002; Fatemi 2005;
Brown 2006; Patterson 2007; Boksa 2008). A large body of
epidemiological data has provided compelling evidence for
enhanced risk of schizophrenia following prenatal exposure
to infection with various viral pathogens, including influenza
(Mednick et al. 1988; Brown et al. 2004), rubella (Brown et
al. 2001), toxoplasma gondii (Brown et al. 2005; Mortensen
et al. 2007), measles (Torrey et al. 1988), polio (Suvisaari et
al. 1999), herpes simplex (Buka et al. 2001), as well as
infection with bacterial pathogens (Sørensen et al. 2008) and
genital and/or reproductive infections (Babulas et al. 2006).
Considering the wide variety of infectious agents involved, it
has been suggested that factors common to the immune
response to a multitude of pathogens may be the critical
mediators of the association between prenatal infection and
enhanced risk of schizophrenia. As discussed in detail
elsewhere (Gilmore and Jarskog 1997; Ashdown et al.
2006; Meyer et al. 2007, 2008a), abnormal expression of
pro-inflammatory cytokines and other mediators of inflam-
mation in the maternal host and eventually in the fetal brain
may interfere with normal fetal brain development. This
early inflammatory insult may predispose the offspring to
long-lasting changes in subsequent brain and behavioral
development and ultimately lead to adult neuropathology
and associated psychosis-related behavior in adolescence or
early adulthood. However, there are several alternative (but
not mutually exclusive) mechanisms whereby prenatal
exposure to infection can bring about changes in brain and
behavioral development (Fatemi 2005; Meyer et al. 2008a).
These include infection-induced stimulation of maternal/fetal
stress response systems (Welberg and Seckl 2001; Koenig et
al. 2002), placental insufficiency (Patterson 2007) and
maternal/fetal nutritional deprivation (Brown et al. 1996;
Brown and Susser 2008; Susser et al. 2008), as well as
penetration of viral pathogens and/or antibodies to the fetal
brain (Whitley and Stagno 1997; Aronsson et al. 2002).
Hence, there are several plausible mechanisms through
which maternal infection during pregnancy can induce an
immunological lesion to the developing fetal brain. Given
that the immuno-precipitated brain lesion takes place early
in development, it can be expected that this leads to wide-
ranging neurodevelopmental sequelae and to multiple
structural and functional brain abnormalities in adult life.
Numerous experimental models of prenatal immune acti-
vation in rats and mice provide direct support for this
hypothesis by demonstrating a wide spectrum of behavioral,
pharmacological, neuroanatomical, and neurochemical
changes in adult offspring born to immune-challenged
mothers (for recent reviews, see Nawa and Takei 2006;
Sullivan et al. 2006; Meyer et al. 2007, 2008a; Meyer and
Feldon 2009). Importantly, many of the functional deficits
induced by prenatal immune challenge in rats and mice are
implicated in some of the most critical phenotypic symptoms
of schizophrenia (Table 1). Furthermore, some of the
behavioral and cognitive deficits induced by in-utero
immune challenge in rats and mice can be normalized by
acute and/or chronic antipsychotic drug treatment in the adult
offspring (Borrell et al. 2002; Shi et al. 2003; Zuckerman et
al. 2003; Zuckerman and Weiner 2005; Ozawa et al. 2006;
Romero et al. 2007), suggesting that the prenatal immune
activation models also fulfill predictive validity for
psychosis-related dysfunctions.
Combined structural and functional investigations in
experimental rodent models indicate that the prenatal
infection-induced functional brain abnormalities at adult
age are closely associated with imbalances in the
mesolimbic and/or mesocortical dopamine (DA) system
(Table 1). Abnormalities in these neurotransmitter systems
are known to be critically involved in the pathophysiology
of schizophrenia and related psychotic disorders (see
below). Hence, disruption of dopaminergic development
may be at the core of the developmental neuropathology
associated with psychosis-related dysfunctions induced by
prenatal exposure to infection. In this review, we integrate
findings derived from experimental models in animals and
parallel research in humans supporting this hypothesis. We
first provide a brief overview of the development and
neuroanatomy of the mesocorticolimbic DA system and its
interconnected brain structures, and summarize the role of
altered DA functions in schizophrenia. Next, we review
experimental findings showing that prenatal immune
activation can lead to long-lasting neuroanatomical and
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neurochemical changes in the mesocorticolimbic DA system,
and discuss the dopamine-associated neural substrates of
psychosis-related behavioral, cognitive, and pharmacological
disturbances induced by prenatal immune challenge. Finally,
we highlight the developmental perspective of abnormal DA
functions following in-utero exposure to infection in relation
to the developmental and maturational mechanisms poten-
tially involved in schizophrenia, and speculate on the
possibility that infection-induced mal-development of the
mesocorticolimbic DA system may be primary to dysfunc-
tions in other cortical and subcortical brain areas and/or
neurotransmitter systems implicated in this disorder.
Anatomy and development of the mesocorticolimbic DA
system
In the adult mammalian brain, the vast majority of
dopaminergic cell bodies are located in discrete mesence-
phalic structures, namely, the substantia nigra (SN) and the
ventral tegmental area (VTA). Dopaminergic cell bodies of
the VTA project to the medial and ventral parts of the
caudate putamen, nucleus accumbens, hippocampus, and
amygdala. These projections form the mesolimbic DA
system. On the other hand, dopaminergic projections from
the VTA to cortical structures, including medial and
dorsolateral parts of the prefrontal cortex (PFC) and
temporal, parietal, and occipital cortices, give rise to the
mesocortical DA pathways. It is well known that both the
mesolimbic and mesocortical DA systems play crucial roles
in the regulation and modulation of cognitive, attentional,
emotional, and reward-related behaviors (reviewed in
Spanagel and Weiss 1999; Nieoullon 2002; Pezze and
Feldon 2004). Dopaminergic cell bodies located in the SN
project primarily to dorsolateral and dorsomedial parts of
the caudate putamen, representing the mesostriatal dopami-
nergic pathway. Integrated in a complex network that
includes other subthalamic and cortical areas, the meso-
striatal DA system is fundamental to the control of
voluntary movements and body posture (Groenewegen
2003). A detailed review of the neuroanatomy and
pharmacology of the mesolimbic, mesocortical, and meso-
striatal DA pathways can be found elsewhere (Joel and
Weiner 2000; Tzschentke 2001; Van den Heuvel and
Pasterkamp 2008).
Mesencephalic DA neurons arise from a common set
of precursor cells early in fetal development. In mice,
proliferation of dopaminergic progenitor cells starts
Table 1 A sample of behavioral, cognitive, and pharmacological phenotypes disrupted by prenatal exposure to infection
Immunogen Species Gestation period Schizophrenia-related functional abnormalities in adult offspring exposed to prenatal immune
challenge
Prepulse inhibition Latent inhibition Sensitivity to AMPH Working memory
Influenza virus Mouse Early/middle ↓ ND ND ND
PolyI:C Mouse Early/middle ↓ ↓ ↑ (↓)
Mouse Middle⟶ late ↓ ND ↑ ↓
Mouse Late – – ↑ ↓
Rat Middle/late ↓ ↓ ↑ ND
LPS Rat Early⟶ late ↓ ND ↑ ND
Rat Middle ↓ ND ND ND
Rat Late ↓ ND ↑ ND
Turpentine Rat Middle ↓ ND ND ND
IL-6 Mouse Early/middle ↓ ↓ ND ND
Rat Early⟶ middle ↓ ↓ ND (↓)
Rat Middle⟶ late ND ND ND ↓
Involvement of mesolimbic DA system ++ +++ +++ +
Involvement of mesocortical DA system ++ −/+ + +++
The table summarizes current animal models demonstrating schizophrenia-related long-term abnormalities emerging following prenatal exposure
to various immunostimulatory agents, including human influenza virus, polyriboinosinic–polyribocytidilic acid (PolyI:C), lipopolysaccharide
(LPS), turpentine, and interleukin-6 (IL-6). The table specifies the precise timing of the prenatal maternal immune challenge as well as the rodent
species used for the experimental investigations. Downward and upward arrows indicate an impairment or enhancement of the particular
phenotype, respectively. Arrows in brackets denote that only modest changes are induced by the prenatal immunological manipulation. The
hyphens indicate that no significant changes were detected relative to the corresponding control treatment. The table also highlights the relative
contribution of dopaminergic imbalances in the mesolimbic and/or mesocortical dopamine (DA) system to each of the listed phenotypic
abnormalities: −/+, weak contribution; +, moderate contribution; ++, substantial contribution; +++, strong contribution. AMPH amphetamine, ND
not determined
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around gestation day (GD) 9.5–10.5 within the caudal
region of the developing mesencephalon and peaks
between GD 12 and 13 (Bayer et al. 1995; Marti et al.
2002). Subsequently, genesis of DA neurons declines.
These cells then migrate to the rostral part of the
mesencephalon during which they continue to develop as
their axons and dendrites form and consolidate connec-
tions with their targets (GD 14 through early postnatal
life) (Riddle and Pollock 2003; Sillitoe and Vogel 2008).
In rats, the same developmental phases occur approxi-
mately 2 days later (Altman and Bayer 1981; Voorn et al.
1988). DA synthesizing neurons in the human fetal brain
are also established very early in development, namely, at
around 5 weeks post-conception (Pickel et al. 1980; Brana
et al. 1996; Aubert et al. 1997). Hence, the cascade of
developmental events that leads to the establishment of the
mesocorticolimbic and mesostriatal DA systems starts
early in fetal life. In most mammalian species, including
humans, monkeys, and rodents, the central DA system
also undergoes significant development and maturation in
the postnatal period. As reviewed elsewhere (Riddle and
Pollock 2003; Burbach and Smidt 2006; Smidt and
Burbach 2007; Van den Heuvel and Pasterkamp 2008),
this includes target selection and collateralization of DA
neurons into the targeted areas as well as pruning and the
programmed cell death of DA innervations.
Altered DA functions in schizophrenia
It has long been recognized that abnormalities in the
central DA system play a major role in the pathophys-
iology of schizophrenia and psychosis-related behavior
(for a recent review, see Goto and Grace 2007; Guillin et
al. 2007; Howes et al. 2007). The original formulation of
the DA hypothesis of schizophrenia was based on
evidence that the therapeutically effective antipsychotic
drugs act, at least in part, by blocking DA receptors,
especially the DA D2 receptor (D2R) subclass (Van
Rossum 1966; Carlsson 1974; Meltzer and Stahl 1976;
Snyder 1976; Seeman 1987, 2006). Further support for
this hypothesis has been yielded by the findings that DA-
stimulating drugs can induce psychosis-like behavior in
non-psychotic human subjects (Angrist and Gershon
1970; Gardner and Connell 1972; Bell 1973) and
aggravate the symptoms in patients with schizophrenia
(Lieberman et al. 1987; Laruelle et al. 1999). This has led
to the original hypothesis that the psychotic symptoms in
schizophrenia are associated with a hyperdopaminergic
state, especially in mesolimbic structures, and that
normalizing enhanced mesolimbic DA activity by DA-
receptor blocking agents is critical for the therapeutic
efficacy of antipsychotic drugs.
Subsequently, the putative impact of a hypofunctioning
cortical DA system has been incorporated into the theories
of altered DA functions in schizophrenia. According to the
revised DA hypothesis of schizophrenia, the central DA
system in this disorder may be characterized by an
imbalance between subcortical and cortical DA systems.
More specifically, it has been suggested that the subcortical
mesolimbic DA system may be hyperactive whilst meso-
cortical DA projections to the PFC may be hypoactive
(Carlsson et al. 2001; Abi-Dargham and Moore 2003;
Laruelle et al. 2003; Winterer and Weinberger 2004; Goto
and Grace 2007; Guillin et al. 2007; Jarskog et al. 2007).
The former abnormalities may be involved in the precipi-
tation of positive symptoms such as hallucinations, delu-
sions, and paranoia, whereas the latter deficits may
critically underlie the emergence of negative and cognitive
symptoms such as social withdrawal, anhedonia, and
impairments in executive functions and working memory.
Prenatal infection: an environmental link to long-term
abnormalities in mescorticolimbic DA functions relevant
to schizophrenia
In-vivo animal models of prenatal immune activation are
indispensable experimental tools to test the hypothesis of
causality and biological plausibility of the human epidemi-
ological association between prenatal exposure to infection
and enhanced risk of schizophrenia-related disorders. They
also provide unique opportunities to explore the underlying
neuroimmunological and neuropathological mechanisms.
Considering the critical role of the mesocorticolimbic DA
system in the pathophysiology of schizophrenia, several
experimental investigations in rats and mice have explored
whether prenatal immune challenge may cause long-term
changes in this neurotransmitter system.
The first direct experimental evidence for prenatal
infection-induced alterations in the mesolimbic DA system
has been provided by the studies of Borrell and colleagues,
who have used a chronic prenatal immune activation model
in rats (Borrell et al. 2002; Romero et al. 2007, 2008). In this
model, pregnant rats are exposed to the bacterial endotoxin
lipopolysaccharide (LPS) throughout gestation, and the brain
and behavioral effects of the prenatal immunological
manipulation are then compared to corresponding control
treatment. LPS is recognized by a specific class of pathogen
recognition receptors referred to as toll-like receptor (TLR) 2
and 4 (Triantafilou and Triantafilou 2002). Upon binding to
these TLRs, LPS stimulates the production and release of
many pro-inflammatory cytokines, including interleukin
(IL)-1β, IL-6, and tumor necrosis factor (TNF)-α (e.g.,
Kimura et al. 1994; Ashdown et al. 2006). Hence,
administration of LPS to mammalian species mimics the
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innate immune response that is typically seen after infection
with Gram-negative bacteria (Triantafilou and Triantafilou
2002).
Using the prenatal LPS model in rats, Borrell and
colleagues have shown that chronic activation of the
maternal immune system increases the immunoreactivity
(IR) of tyrosine hydroxylase (TH) in the nucleus accum-
bens (NAc) of the adult offspring, especially in the NAc
shell subregion (Borrell et al. 2002). TH is the rate-limiting
enzyme of DA (and noradrenaline) synthesis in vivo, and it
can therefore be used as a pre-synaptic dopaminergic
marker (Bacopoulos and Bhatnagar 1977). The increase in
NAc TH-IR in adult rats prenatally exposed to LPS is
paralleled by enhanced basal levels of DA in this brain area
as well as by increased levels of the DA metabolite
dihydroxyphenylacetic acid (DOPAC) in more dorsal parts
of the striatum (Romero et al. 2007, 2008).
A causal link between prenatal immune challenge and the
emergence of long-term abnormalities in the mesocorticolim-
bic DA system has also been found in experimental rodent
models that are based on prenatal treatment with the viral
mimic polyriboinosinic–polyribocytidilic acid (PolyI:C).
PolyI:C is a synthetic analogue of virus-specific double-
stranded RNA, which is recognized by the pathogen recogni-
tion receptor TLR3 (Alexopoulou et al. 2001; Takeuchi and
Akira 2007). In addition to stimulating pro-inflammatory
cytokine responses, PolyI:C is a potent inducer of the type I
interferons IFN-α and IFN-β. Administration of PolyI:C to
mammalian species can thus be used to mimic the acute
phase response to viral infection (Fortier et al. 2004b; Traynor
et al. 2004; Cunningham et al. 2007).
Consistent with the findings in the LPS model in rats
(Borrell et al. 2002), acute prenatal treatment with the viral
mimic PolyI:C in early/middle gestation (GD 9) in mice
leads to enhanced TH-IR in the NAc at adult age (Meyer et
al. 2008c). Importantly, the implementation of neonatal
cross-fostering procedures in this model suggests that the
effects of prenatal immune activation on altered accumbal
TH expression are attributable to prenatal but not postnatal
maternal effects on the offspring. This is because enhanced
accumbal TH-IR was found in prenatally PolyI:C-treated
offspring regardless of whether they were raised by
surrogate mothers, which had experienced PolyI:C treat-
ment during pregnancy, or whether they were adopted by
sham-treated control surrogate mothers (Meyer et al.
2008c). The prenatal PolyI:C-induced effects on accumbal
TH expression are paralleled by a marked increase in the
basal levels of the DA metabolite homovanillic acid (HVA)
in the NAc, but not by altered accumbal DA levels or its
metabolite DOPAC (Winter et al. 2008). The null effect of
acute prenatal PolyI:C treatment on basal striatal DA levels
in mice corroborates the findings by Zuckerman et al.
(2003), who have demonstrated that a single exposure to
PolyI:C in middle/late gestation (GD 15) in rats does not
affect basal striatal DA release in vitro but leads to
enhanced striatal DA release only following KCl-induced
stimulation. DA-related abnormalities have also been
detected in adult mice following sub-chronic treatment
with the viral mimic PolyI:C on six consecutive days from
GDs 12 to 17 (Ozawa et al. 2006). This prenatal
immunological manipulation has been shown to result in a
striatal dopaminergic hyperfunction at adult age, which
manifests itself in increased striatal DA turnover (as
indexed by the DOPAC+HVA/DA ratio) and decreased
receptor binding of DA D2-like receptors in striatal regions.
In addition to abnormalities in the accumbal DA system,
experimental studies using the PolyI:C model in mice have
provided evidence that prenatal immune challenge can lead
to long-lasting changes in the prefrontal cortical DA system.
Post-mortem immunohistochemical investigations have
revealed a significant decrease in the expression of D1R
and D2R in the PFC of adult mice born to PolyI:C-treated
mothers compared with offspring born to control mothers
(Meyer et al. 2008c, d). Again, cross-fostering procedures in
this model have verified the prenatal nature of these DA-
related deficits in the PFC (see Meyer et al. 2008c). At the
neurochemical level, prenatal PolyI:C-induced immune
challenge has been shown to significantly increase the
basal levels of DA in prefrontal cortical areas (Winter et al.
2008). One implication would therefore be that the decrease
in prefrontal D1Rs and D2Rs induced by prenatal immune
activation may reflect a counter-regulatory mechanism for
increased basal DA levels in this brain area.
Taken together, there is considerable evidence derived
from experimental models in animals that prenatal immune
activation can negatively affect the normal development of the
mesocorticolimbic DA system. The reported effects have clear
relevance to schizophrenia, because similar neuropathological
deficits have also been noted in patients suffering from this
disorder. For example, there is biochemical evidence of
enhanced levels of DA and its metabolites DOPAC and
HVA in dorsal and ventral striatal regions (e.g., Mackay et al.
1982; Toru et al. 1982, 1988). Interestingly, the abnormal
basal levels of DA and its metabolites appear to be linked to
increased TH activity in these brain regions (Toru et al. 1982,
1988), similar to the effects reported in experimental models
of prenatal immune challenge (Borrell et al. 2002; Meyer et
al. 2008c). In addition to these pre-synaptic abnormalities,
adult rats and mice exposed to prenatal immune challenge
also display enhanced striatal DA release following KCl-
induced stimulation (Zuckerman et al. 2003) and increased
behavioral sensitivity to acute treatment with low doses of
the indirect DA receptor agonist amphetamine (AMPH; see
below). These dopaminergic abnormalities are suggestive of
some of the most consistent pre-synaptic abnormalities
observed in patients with schizophrenia, namely elevated
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striatal DA release following acute AMPH challenge (Laruelle
et al. 1996, 1999; Breier et al. 1997; Abi-Dargham et al.
1998) and elevated striatal DA synthesis capacity (Hietala et
al. 1995, 1999; Lindstrom et al. 1999; for a recent review,
see Howes et al. 2007). Furthermore, some of the DA
receptor changes emerging in adult offspring born to
immune-challenged mothers are also reminiscent of critical
neuropathological signs in schizophrenia. For example, there
is evidence from brain imaging studies that prefrontal D1Rs
are reduced at least in a subgroup of schizophrenic patients,
especially in those with marked negative symptoms (Okubo
et al. 1997a, b; but see also Abi-Dargham et al. 2002, Abi-
Dargham and Moore 2003). In addition, some studies
demonstrate that receptor binding of DA D2-like receptors
is decreased in the striatum of drug-free schizophrenic
patients (Reynolds et al. 1980; Mackay et al. 1982; Dean et
al. 2004). However, it needs to be emphasized that the
findings of striatal D2R alterations in schizophrenia remain
highly controversial. Indeed, in contrast to studies reporting
decreased receptor binding of DA D2-like receptors in the
striatum (Reynolds et al. 1980; Mackay et al. 1982; Dean et
al. 2004), several studies found an increase (e.g., Crawley et
al. 1986; Wong et al. 1986) or no changes (Farde et al. 1990;
Martinot et al. 1990) in D2R binding in the striatum of
patients with schizophrenia relative to healthy controls (for a
recent review, see Howes et al. 2007).
DA-related brain and behavioral relationships
in prenatal infection-induced psychotic behavior
The DA-related neuropathological changes in adult off-
spring born to immune-challenged rats and mice are
accompanied by a wide spectrum of behavioral, cognitive,
and pharmacological abnormalities implicated in psychotic
disorders (for a summary, see Table 1). This includes
disruption of sensorimotor gating (Borrell et al. 2002; Shi et
al. 2003; Meyer et al. 2005, 2008b, d; Ozawa et al. 2006;
Fortier et al. 2007; Romero et al. 2007, 2008; Smith et al.
2007; Wolff and Bilkey 2008), abnormalities in selective
learning and attentional control (Zuckerman et al. 2003;
Zuckerman and Weiner 2005; Meyer et al. 2005, 2006a, c,
2008b; Smith et al. 2007), enhanced sensitivity to psycho-
stimulant drugs (Zuckerman et al. 2003; Zuckerman and
Weiner 2005; Fortier et al. 2004a; Meyer et al. 2005,
2008b, c, d), as well as deficits in working memory (Meyer
et al. 2005, 2008d), and reversal learning (Zuckerman and
Weiner 2005; Meyer et al. 2006b). It is well known that the
mescorticolimbic DA system plays a prominent role in the
expression and modulation of these neuropsychological,
neurocognitive, and neurochemical functions, and distur-
bances within this neurotransmitter system are believed to
be a critical pathophysiological mechanism for their
disruption in schizophrenic patients (Creese and Iversen
1975; Gray et al. 1991; Deutch 1992; Goldman-Rakic
1996, 1998; Swerdlow and Geyer 1998, 2001; Nieoullon
2002; Weiner 2003; Robbins 2005; Williams and Castner
2006; Goto and Grace 2008) (Table 1). For example,
numerous experimental investigations in rats and mice
demonstrate that manipulations leading to enhanced activity
in the mesolimbic DA system, especially in the NAc,
robustly disrupt sensorimotor gating in the form of prepulse
inhibition (PPI) of the acoustic startle reflex and selective
associative learning in the form of latent inhibition (LI)
(reviewed in Koch and Schnitzler 1997; Koch 1999;
Swerdlow and Geyer 1998, 2001; Moser et al. 2000;
Weiner 2003). Furthermore, enhanced behavioral reactions
to low doses of the dopaminergic psychostimulant drug
AMPH are often suggestive of functional overactivity of
mesolimbic (and especially mesoaccumbal) DA pathways
(Creese and Iversen 1975; Pijnenburg et al. 1976; Weiner et
al. 1996; Heidbreder and Feldon 1998). Hence, the prenatal
infection-induced changes in the mesolimbic DA system
may provide a plausible neuronal mechanism for some of
the pathological core symptoms in adult offspring born to
immune-challenged mothers. This hypothesis is further
supported by the findings that pharmacological treatment
with the preferential D2R blocker haloperidol is sufficient
to normalize some of the prenatal infection-induced
functional disturbances linked to a hyperdopaminergic state
in mesolimbic structures, including disruption of sensori-
motor gating and latent inhibition (Borrell et al. 2002;
Zuckerman et al. 2003; Zuckerman and Weiner 2005;
Romero et al. 2007).
In addition to the suggested involvement of abnormal
mesolimbic DA functions, morphological and neurochem-
ical alterations in the prefrontal DA system may also
significantly contribute to some of the behavioral and
cognitive disturbances in adult offspring born to immune-
challenged mothers. It is known that normal working
memory functions are crucially dependent on the integrity
of the prefrontal cortical DA system (Goldman-Rakic 1996,
1998). Interestingly, DA signaling at D1R in the PFC
exhibits an inverted U-shape relationship: Both insufficient
and excessive prefrontal DA signaling can lead to working
memory deficits, especially in the spatial domain (reviewed
in Williams and Castner 2006). Reduced expression of
prefrontal D1Rs (Meyer et al. 2008c, d), together with the
concomitant changes in basal DA levels in this area (Winter
et al. 2008), may thus be one of the critical neuronal
substrates of working memory deficiency in prenatally
immune-challenged subjects.
Altered DA-associated signaling in the PFC may also play
an important contribution to the emergence of sensorimotor
gating deficits in adult offspring born to immune-challenged
mothers. Although the precise role of the prefrontal DA
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system in the regulation and modulation of PPI still remains
to be explored (Koch and Bubser 1994; Bast et al. 2002;
Swerdlow et al. 2005, 2006), several findings from previous
experimentation in rodents can be taken as additional support
for this hypothesis: Pharmacological blockade of D1Rs in
the PFC significantly attenuates PPI in rats, indicating that
impaired prefrontal D1R-mediated signaling can lead to
sensorimotor gating deficiency (Ellenbroek et al. 1996;
Shoemaker et al. 2005). Furthermore, selective enhancement
of dopaminergic activity in the PFC by micro-infusion of the
direct dopamine receptor agonist apomorphine has been
shown to disrupt PPI in rats (Broersen et al. 1999; Lacroix et
al. 2000). Interestingly, this effect is enhanced by simulta-
neous blockade of D1Rs in the PFC (de Jong and van den
Buuse 2006). The concomitant reduction in prefrontal D1Rs
(Meyer et al. 2008c, d) and increase in basal DA levels
(Winter et al. 2008) may thus provide an additional neural
basis for sensorimotor gating dysfunctions in adult offspring
born to immune-challenged mothers.
Developmental perspective of abnormal DA functions
following prenatal immune challenge
The onset of full-blown psychopathological symptoms
in schizophrenia typically occurs in adolescence or early
adulthood (Weinberger 1987; Rapoport et al. 2005;
Tamminga and Holcomb 2005). One prevalent hypothesis
suggests that this maturational dependency is related to the
functional maturation of intracortical connectivity, espe-
cially within prefrontal–temporolimbic cortical pathways
(Weinberger 1987; Weinberger and Lipska 2005; Keshavan
and Hogarty 1999). Early developmental defects of the
temporolimbic cortex and its connectivity may subsequently
affect mesolimbic DA functions and induce DA-dependent
psychotic abnormalities (Weinberger 1987; Weinberger and
Lipska 2005). However, prior to adult life, the impact of
developmental lesions to the temporolimbic system on
behavioral functions may be compensable, partly because
dysfunctions of the subcortical neural circuits affected by the
lesion do not critically disrupt dopaminergic functions. This
further implies that subcortical dopaminergic systems come
under more extensive control as intracortical neural circuit-
ries mature, so that dysfunctions of this circuitry will have a
greater influence on dopaminergic activity after it has
reached the critical developmental stage after puberty
(Weinberger 1987; Weinberger and Lipska 2005; Keshavan
and Hogarty 1999). Taken together, enhanced mesolimbic
(especially striatal) dopaminergic activity as seen in schizo-
phrenic patients may be induced by early developmental
defects of (non-dopaminergic) prefrontal–temporolimbic
cortical pathways and may thus emerge secondarily to
disturbances in other brain regions, particularly in prefrontal
(Feinberg 1982; Weinberger 1987; Deutsch 1992; Weinberger
and Lipska 2005; Laruelle et al. 2003; Grace 2004) and/or
hippocampal (Weiner 1990; Gray et al. 1991, Gray 1998;
Grace 2000; Velakoulis et al. 2000; Phillips et al. 2006)
structures (see Fig. 1a). Experimental studies in rats support
this hypothesis by showing that early disruption of prefrontal–
temporolimbic cortical pathways by neonatal lesion of the
ventral hippocampus leads to the post-pubertal emergence of
numerous DA-associated behavioral and neurochemical ab-
normalities implicated in schizophrenia (reviewed in Lipska
and Weinberger 2000; Lipska 2004). Subsequent theories
have further refined this hypothesis by emphasizing the
potential contribution of a hypoglutamatergic state to meso-
limbic and mesocortical DA imbalances. More specifically, it
has been suggested that the critical DA abnormalities in
schizophrenia (i.e., striatal excess and cortical deficiency of
DA) might be secondary to hypofunctions of glutamatergic
signaling at N-methyl-D-aspartate (NMDA) receptors in the
PFC (for a review, see Carlsson et al. 2001; Laruelle et al.
2003).
Consistent with the post-pubertal onset of full-blown
psychotic behavior in schizophrenia, most of the psychosis-
related functional brain effects of prenatal immune challenge
appear to be dependent on post-pubertal maturational
processes. Experimental investigations in rats and mice
show that various DA-related behavioral, cognitive, and
pharmacological abnormalities induced by prenatal exposure
Fig. 1 Primary versus secondary neuronal contributions to meso-
corticolimbic dopamine dysfunctions in psychosis-related disorders.
Primary and secondary mechanisms are represented in solid and
dashed lines, respectively. a Abnormalities in the mesoaccumbal
(VTA⟶ NAc) and mesocortical (VTA⟶ PFC) dopamine systems
(highlighted in red) may be secondary to dysfunctions in other
neurotransmitter systems and/or brain areas. According to this model,
the primary mechanisms for imbalances in the mesocorticolimbic
dopamine systems involve diminished inhibitory control of the VTA
and/or NAc from PFC and/or HPC (for a detailed discussion, see
Carlsson et al. 2001 and Laruelle et al. 2003). b Alternatively,
abnormalities in the mesoaccumbal and mesocortical dopamine
systems may stem from primary developmental defects and may thus
exist prior to alterations in other neurotransmitter systems and/or brain
areas. Primary defects in the mesocorticolimbic dopamine system may
induce subsequent changes in PFC and/or HPC structure and function,
which in turn may further modulate the activity of mesoaccumbal and
mesocortical dopaminergic functions. Primary defects in the meso-
corticolimbic dopamine may arise from neurodevelopmental defects
associated with (but not limited to) prenatal exposure to infection
during early stages of fetal life. HPC, hippocampus; NAc, nucleus
accumbens; PFC, prefrontal cortex; VTA, ventral tegmental area
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to the viral mimic PolyI:C, or the bacterial endotoxin LPS,
only emerge at post-pubertal but not juvenile or pre-pubertal
stages of life (Zuckerman et al. 2003; Zuckerman and
Weiner 2003; Meyer et al. 2006c, 2008c; Ozawa et al.
2006; Romero et al. 2008). In keeping with the develop-
mental mechanisms outlined above, one possible explana-
tion for this delayed onset of symptoms would be that the
underlying mesocorticolimbic DA disturbances are only
secondary to maturation-dependent dysfunctions in other
brain regions and/or neurotransmitter systems. According to
this interpretation, maternal infection during pregnancy
would not directly affect the development and functioning
of the offspring’s DA system, but would lead instead to a
developmental disruption of other neurotransmitter systems,
which would then trigger subsequent functional imbalances
in the mesocorticolimbic DA system and precipitate DA-
associated psychotic disturbances in adulthood.
Contrary to this suggestion, however, several experimental
investigations in rats and mice highlight that at least some of
the prenatal infection-induced brain and behavioral abnormal-
ities may stem from primary developmental defects of the
mesocorticolimbic DA system (see Fig. 1b). The first line of
evidence is derived from the recent findings that prenatal
immune challenge can lead to enhanced behavioral sensitivity
to acute dopaminergic stimulation by AMPH treatment
already at the pre-pubertal stage of development (Meyer et
al. 2008c), provided that prenatal immunological insult takes
place during early fetal development (for a comparison in
mice, see Ozawa et al. 2006 and Meyer et al. 2008c; for rats,
see Zuckerman et al. 2003). Hence, distinct forms of
schizophrenia-related psychopathology are manifested at
different stages of postnatal development after early prenatal
exposure to immune challenge in mice: Whilst abnormal
selective associative learning (Meyer et al. 2006c), disrupted
sensorimotor gating (Meyer, Vuillermot, Feldon; unpublished
observation), and enhanced responding to acute NMDA-
receptor antagonism by systemic dizocilpine (MK-801)
treatment (Meyer et al. 2008c) only appear at adult age,
early fetal brain inflammation leads to enhanced AMPH
sensitivity already in pre-adolescence (Meyer et al. 2008c).
Considering the known involvement of the mesolimbic
(especially mesoaccumbal) DA system in mediating the
behavioral effects of acute AMPH exposure (Creese and
Iversen 1975; Pijnenburg et al. 1976; Weiner et al. 1996;
Heidbreder and Feldon 1998), the potentiation of AMPH
sensitivity emerging in pre-pubertal offspring born to gesta-
tionally immune-challenged mothers points to the existence
of subcortical DA imbalances before (prefrontal) cortical
structures reach maximal control over subcortical DA systems
in adulthood (Feinberg 1982; Weinberger 1987; Weinberger
and Lipska 2005; Keshavan and Hogarty 1999; Finlay 2001;
Tsujimoto 2008). One implication is that immune activation
in early fetal life may induce DA-associated endogenous
sensitization mechanisms during peri-adolescent develop-
ment, which precede the onset of the full spectrum of
schizophrenia-related abnormalities in adulthood. This idea is
indeed central to the endogenous sensitization theory of
schizophrenia, which suggests that dopaminergic transmis-
sion in psychosis-prone individuals may already function in a
sensitized state before the onset of full-blown psychotic
behavior (Laruelle 2000; Howes et al. 2004, 2007, 2009;
Collip et al. 2008).
A second line of evidence for primary dopaminergic
disturbances in the development of prenatal infection-
induced, psychotic abnormalities is derived from experimen-
tal investigations designed to study the acute effects of early
gestational maternal immune activation on fetal dopaminer-
gic development: Using the PolyI:C model of prenatal
immune challenge, we have recently shown that maternal
immunological stimulation in early/middle pregnancy
(GD 9) increases the number of mesencephalic DA neurons
in the fetal VTA/SN at middle/late (GD 13) and late (GD 17)
stages of prenatal development (Meyer et al. 2008e). This
effect is paralleled by changes in fetal expression of several
genes known to be involved in DA neuron development,
including the inductive signals sonic hedgehog (Shh) and
fibroblast growth factor 8 (Fgf8), as well as the transcription
factors Nurr1 and Pitx3 (Meyer et al. 2008e). Notably, these
findings do not provide a direct link between altered fetal
dopaminergic development and the emergence of dopamine-
associated structural and functional abnormalities in the
postnatal period. However, these results highlight the
possibility that postnatal dopaminergic abnormalities emerg-
ing after prenatal immune challenge are of developmental
origin starting early in fetal life. In particular, infection-
induced abnormalities in the development of fetal VTA/SN
DA neurons may represent an important primary mechanism
for the postnatal emergence of psychosis-related functional
and structural changes associated with imbalances in the
mescorticolimbic DA system.
The feasibility and biological plausibility of primary
dopaminergic mechanisms in the development of
schizophrenia-related dysfunctions is also supported by
several additional experimental investigations in mice.
Rojas and colleagues (2007) have recently demonstrated
that genetically induced reductions in the expression of the
transcription factor Nurr1 lead to adult behavioral and
neurochemical dysfunctions with potential relevance to
schizophrenia. At the neurochemical level, these include
reduced DA turnover in striatal regions and enhanced DA
turnover in the PFC; at the behavioral level, adult mice with
reduced Nurr1 expression display enhanced stress or drug-
induced locomotor activity as well as deficient retention in
emotional memory (Eells et al. 2002; Bäckman et al. 2003;
Rojas et al. 2007). Similar findings have also been found
following genetic disruption of the Fgf receptor-1 (FgfR1)
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in mice (Klejbor et al. 2006). As already mentioned, both
Nurr1 and Fgf are critically involved in early dopaminergic
development, and disruption of Nurr1- and/or Fgf-mediated
signaling can lead to profound and persistent disturbances
in the development of midbrain DA systems (Zetterström et
al. 1997; Smits et al. 2003; Burbach and Smidt 2006; Smidt
and Burbach 2007). Therefore, the identified neurochemical
and behavioral abnormalities in Nurr1- and FgfR1-deficient
mice (Eells et al. 2002; Bäckman et al. 2003; Klejbor et al.
2006; Rojas et al. 2007; Moore et al. 2008) provide a
genetic link between primary developmental disturbances
in the central DA system and the emergence of long-lasting
brain and behavioral changes relevant to schizophrenia.
Another line of evidence for primary dopaminergic
mechanisms in the development of psychosis-related abnor-
malities is obtained by the findings of Kellendonk and
colleagues (2006), who have demonstrated that transient and
selective overexpression of D2Rs in the striatum induces
persistent abnormalities in PFC functioning. These include
deficits in working memory and behavioral flexibility,
increased basal DA levels and reduced DA turnover in the
PFC, and altered D1R-mediated signaling in the PFC
(Kellendonk et al. 2006). The great relevance of this study
is that it clearly demonstrates that schizophrenia-related
abnormalities involving PFC-dependent functions can emer-
gence secondarily to changes in striatal DA receptor
expression during pre- to postnatal brain development.
Indeed, switching off striatal D2R overexpression in adult
animals does not reverse the alterations in PFC functions,
suggesting that the deficits result from early developmental
but not concurrent functioning of enhanced striatal D2Rs
(Kellendonk et al. 2006).
Predictions and opportunities associated with primary
dopaminergic mechanisms in schizophrenia
If psychotic dysfunctions emerging at post-pubertal stages
of life were indeed accounted for by primary defects in the
development and/or functioning of the mesocorticolimbic
DA system, then one immediate expectation would be that
the onset of post-pubertal abnormalities can be prevented
by appropriate interventions targeting abnormal develop-
ment and/or maturation of the mesocorticolimbic DA
system. Our recent experimental investigations designed
to study the preventive effects of peri-adolescent pharma-
cological interventions in an infection-based neurodevelop-
mental mouse model of schizophrenia-like disorder fulfilled
this expectation. We have shown that peri-adolescent
treatment with the preferential D2R antagonist haloperidol
is sufficient to prevent the emergence of multiple
psychosis-related behavioral and pharmacological abnor-
malities in mice predisposed to adult brain pathology by
exposure to prenatal immune challenge (Meyer et al.
2008f). In this study (Meyer et al. 2008f), pregnant mice
were exposed to PolyI:C or corresponding control treatment
on GD 9, and the resulting offspring were then subjected to
chronic haloperidol (or other antipsychotic or antidepres-
sant drug) treatment during the peri-adolescent stage of
development (i.e., between postnatal days 35 and 65).
Adult behavioral and pharmacological functions in drug-
treated PolyI:C and control offspring were then compared
to corresponding offspring receiving placebo treatment
during the peri-adolescent stage of development. Impor-
tantly, all the phenotypic characterization of drug- and
placebo-treated offspring was conducted in a drug-free state
following a drug wash-out period of 3 weeks, thus avoiding
possible confounds arising from acute drug effects. We
found that peri-adolescent haloperidol treatment in PolyI:C
offspring was effective for the prevention of numerous
abnormalities known to be associated with imbalances in
the mesocorticolimbic DA system, namely deficiency in
selective associative learning in the form of latent inhibition
disruption and increased sensitivity to acute treatment with
the indirect dopamine receptor agonist AMPH and the non-
competitive NMDA-receptor antagonist MK-801 (Meyer et
al. 2008f). Hence, in the absence of preventive pharmaco-
therapy, offspring born to PolyI:C-challenged mothers
developed multiple schizophrenia-related abnormalities in
adulthood, whereas PolyI:C offspring treated with haloper-
idol for preventive reasons did not. Even though the precise
underlying molecular mechanisms remain to be elucidated,
these findings indicate that the efficacy of peri-adolescent
haloperidol treatment to block the emergence of prenatal
PolyI:C-induced deficits in adulthood may be associated
with the drugs’ effects on processes occurring during peri-
adolescent development of the mesocorticolimbic DA
system.
Another prediction associated with the hypothesis of
primary defects in the development and/or functioning of
the mesocorticolimbic DA system would be that the
extent and nature of the deficits may critically differ as a
function of the timing of the infection-induced early
brain lesion. More specifically, given that mesencephalic
DA neurons forming the fetal VTA are established very
early in prenatal development (see above), one would
expect that primary defects in the mesocorticolimbic DA
system would be more readily seen following immune
activation during early stages of fetal life compared to
late fetal immune challenge. Direct evidence for this
possibility is still lacking. However, this expectation is
not unprecedented, because the precise timing of prenatal
immune challenge is known to critically determine the
specificity of adult brain and behavioral dysfunctions
(Meyer et al. 2006a, b, 2007, 2008d; Fortier et al. 2007;
Fatemi et al. 2008).
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The possible existence of primary etiopathological dopa-
minergic mechanisms in the development of psychosis-related
abnormalities in general, and following prenatal immune
activation in particular, may also have important implications
for the identification of individuals at high risk for full-blown
psychotic disorders. It has long been recognized that the full
spectrum of psychotic symptoms in schizophrenia is preceded
by a muted form of psychosis-related behavior. This early
phase of the disorder is commonly referred to as the (initial)
prodromal phase (McGlashan 1996; Klosterkötter et al. 2001;
Lieberman et al. 2001; Cornblatt and Auther 2005). During
this phase, subjects often display relatively unspecific
pathological symptoms, including anxiety, depression, social
withdrawal, and subtle neurocognitive deficits. Individuals
prodromally symptomatic for schizophrenia also appear to
suffer from attenuated forms of psychopathology typically
seen in schizophrenic patients with marked positive symptoms.
These include phases of hallucinations, delusions, and para-
noia, which are not as frequent and/or severe as in patients with
schizophrenia (McGlashan 1996; Klosterkötter et al. 2001;
Lieberman et al. 2001; Cornblatt and Auther 2005). However,
a relatively unknown factor is the conversion rate amongst
individuals identified as being at high risk for full-blown
psychosis. Based on the existing identification criteria, only
20–50% of the subjects indentified as being at high risk go on
to develop the full-blown psychotic disorder within 1–2 years
(Yung et al. 1998, 2003; Corcoran et al. 2005).
Given that increased behavioral and neurochemical
responses to acute treatment with low doses of AMPH is
one of the critical pathological phenotypes associated
with the positive symptoms of schizophrenia (Laruelle et
al. 1996, 1999), enhanced sensitivity to acute AMPH
exposure in individuals assumed to be at high risk of
schizophrenia may be used as prodromal phenotype
predicting the subsequent progression into full-blown
psychotic disorder. Following our experimental findings
(see Meyer et al. 2008c), one prediction would be that
prodromal patients converting to the full-blown disorder
may already display enhanced behavioral and/or neuro-
chemical responses to acute dopaminergic stimulation by
systemic AMPH treatment. This is in line with the
hypothesis put forward by Howes and colleagues (2007)
suggesting that the at-risk mental state existing in the
prodromal phase of schizophrenia may be associated with
striatal hyperdopaminergia. Howes and colleagues have
recently found direct evidence for this hypothesis by
showing that striatal overactivity precedes the onset of
schizophrenia in individuals with prodromal psychotic
symptoms (Howes et al. 2009). Furthermore, there is
recent evidence indicating that individuals at high risk of
psychosis display enhanced stress-induced DA release in
ventral striatal regions (Soliman et al. 2008). Since stress
exposure is known to stimulate dopaminergic transmission
in the mesocorticolimbic DA system in a similar way to
acute AMPH treatment (Finlay and Zigmond 1997), this
may additionally point to the existence of (mesocortico-
limbic) dopaminergic hyperfunctions preceding the onset
of full-blown psychotic disorder.
Summary and conclusions
Recent experimental investigations have provided consider-
able evidence that prenatal immune challenge can negatively
affect normal mesocorticolimbic DA functions and lead to
DA-dependent behavioral, cognitive, and pharmacological
abnormalities implicated in schizophrenia. Imbalances in the
mesocorticolimbic DA system appear to be among the core
neuronal deficits underlying the emergence of psychosis-
related symptoms following prenatal exposure to infection.
Prenatal exposure to infection may thus be a significant
environmental risk factor for dopaminergic dysfunctions in
this disorder. This is consistent with the hypothesis that many
of the developmental risk factors which increase the risk of
schizophrenia appear to act by facilitating dopamine dysre-
gulations (Di Forti et al. 2007; Murray et al. 2008).
The existence of core dysfunctions in the mesocorti-
colimbic DA system does not exclude the possibility
that dysfunctions in other neurotransmitter systems may
also significantly contribute to the emergence of
psychosis-related behavior following prenatal exposure
to infection. Indeed, a given behavioral trait is typically
regulated by multiple interconnected brain structures,
and disturbances at many sites within a complex
neuronal circuitry can give rise to a similar pathological
phenotype (O’Donnell and Grace 1998). Considering that
infection-induced interference with early brain develop-
ment can lead to abnormalities in multiple brain areas and
neurotransmitter systems (reviewed in Meyer et al. 2007;
Meyer and Feldon 2009), it seems unlikely that a specific
pathological phenotype at the functional level is accounted
for by dysfunctions in isolated brain structures. Therefore,
disturbances in other neurotransmitter systems, including
the GABAergic, glutamatergic, and serotonergic systems,
may modulate the impact of mesocorticolimbic DA
abnormalities on prenatal infection-induced psychotic
disorders (for a detailed discussion, see Meyer and Feldon
2009). However, given that infection-induced abnormali-
ties in the mesocorticolimbic DA system seem to start
very early in brain development, mal-development in this
neurotransmitter system may represent the primary etio-
pathological mechanism in the development of psychotic
disorders following in-utero exposure to infection
(Fig. 1b). This hypothesis differs from the view that
dopaminergic abnormalities in schizophrenia may be
secondary to abnormalities in other brain areas and/or
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neurotransmitter systems, including deficient NMDA-
mediated signaling in prefrontal and hippocampal structures
(Fig. 1a).
The precise developmental mechanisms whereby primary
dopamine dysregulations can lead to secondary abnormalities
in other brain areas and neurotransmitter systems relevant to
schizophrenia remain to be elucidated. However, one possi-
bility would be that dopaminergic abnormalities existing
during the course of postnatal brain development may alter the
organism’s sensitivity to environmental stimuli, including
reward and stress. Such stimuli are well known to activate
mesocorticolimbic DA transmission (Horger and Roth 1996;
Finlay and Zigmond 1997; Spanagel and Weiss 1999; Pani et
al. 2000). Primary dysfunctions in the mesocorticolimbic
dopamine system may significantly alter the responsiveness
to rewarding and stressful stimuli; and this may, in turn,
induce secondary structural adaptations in cortical and
subcortical brain areas, including hippocampus and prefron-
tal cortex. Indeed, as extensively reviewed elsewhere
(McEwen 2001, 2007; Romeo and McEwen 2006), both
hippocampus and PFC undergo stress-induced structural
remodeling, which can ultimately precipitate hippocampal
and prefrontal cortical dysfunctions relevant to schizophrenia
and related disorders (Hains and Arnsten 2008). Hence, the
hypothesis of primary dysfunctions in the mesocorticolimbic
DA system may not only provide an important environmen-
tal link between prenatal exposure to infection and enhanced
risk of schizophrenia but it may also explain abnormalities in
other brain areas implicated in this disorder. Further
investigations of the underlying cellular and molecular
mechanisms are thus clearly warranted in order to verify
whether the hypothesis of primary DA dysfunctions may be
specific to individuals predisposed to psychotic disorders by
prenatal infection or whether this may represent a general
etiopathological mechanism involved in the development of
schizophrenia and other psychotic disorders.
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